Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135313 | 1.00 | LMNA (0.51) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL204119 | 1.00 | LMNA (0.51) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL542561 | 0.82 | LMNA (0.53) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL20134878 | 0.82 | LMNA (0.53) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL542817 | 0.81 | LMNA (0.51) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL17054772 | 0.81 | MEN1 (0.55) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL7099930 | 0.81 | LMNA (0.51) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL17570773 | 0.81 | LMNA (0.51) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL10131744 | 0.81 | LMNA (0.51) | LMNAMEN1KMT2ATNKSMMP2 | |
| SCHEMBL17055125 | 0.81 | MEN1 (0.55) | LMNAMEN1KMT2ATNKSMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670738-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012104263-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | WO | disclosed |
| EP-0903353-B1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-25 | — | — | EP | disclosed |
| EP-0816343-B1 | Process for the preparation of chiral, non-racemic (4-aryl-2,5-dioxoimidazolidin-1-yl)-acetic acids | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-12-14 | — | — | EP | disclosed |
| EP-0811616-B1 | Salts of 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3-phenyl-propionic acid ethylester | AVENTIS PHARMA GMBH (DE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| US-6759424-B2 | 2,5-DIOXOIMIDAZOLIDINE OR 2-THIO-5-OXOIMIDAZOLIDINE DERIVATIVES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| CN-1125054-C | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICS GMBH (DE) | 2003-10-22 | — | — | CN | disclosed |
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
| EP-0842943-B1 | 5-Ring heterocycles as inhibitors of leukocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6423712-B1 | 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-23 | — | — | US | disclosed |
| US-6294562-B1 | AMIDINO COMPOUNDS WITH AMIDO ESTERS CARDIOVASCULAR SYSTEM, DISEASES OF THE CORONARY VASCULAR SYSTEM OR THE CEREBROVASCULAR SYSTEM, OR PERIPHERAL ARTERIAL VASCULAR DISEASE | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-09-25 | — | — | US | disclosed |
| US-6018053-A | Process for the preparation of chiral, nonracemic (4-aryl-2,5-dioxoimidazolidin-1-yl) acetic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-25 | — | — | US | disclosed |
| US-5939556-A | Hydantoin compounds, salts thereof, processes for their preparation, and processes for preparing pharmaceutically active compounds comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-17 | — | — | US | disclosed |
| EP-0903353-A1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-24 | — | — | EP | disclosed |
| EP-0842943-A2 | 5-Ring heterocycles as inhibitors of leukocyte adhesion and as VLA-4 antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0823898-A1 | HYDANTOINE DERIVATIVES AS INTERMEDIATE PRODUCTS FOR ACTIVE PHARMACEUTICAL AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-18 | — | — | EP | disclosed |
| EP-0816343-A1 | Process for the preparation of chiral, non-racemic (4-aryl-2,5-dioxoimidazolin-1-yl)-acetic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | disclosed |
| EP-0811616-A1 | Salts of 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3-phenyl-propionic acid ethylester | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996033976-A1 | HYDANTOINE DERIVATIVES AS INTERMEDIATE PRODUCTS FOR ACTIVE PHARMACEUTICAL AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | LMNA 1233/4885MEN1 4547/4885KMT2A 2615/4885 |
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | VCAM1, ITGA1, ITGA4 | LMNA 1133/4885MEN1 4123/4885KMT2A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.